PharmaCARE Ethics: IP, Safety, and Legal Liability
This paper examines the ethical and legal issues surrounding PharmaCARE's creation of CompCARE, a compounding pharmacy established to bypass FDA oversight and accelerate the sale of drug AD23. The analysis covers PharmaCARE's violations of direct-to-consumer marketing regulations, its failure to disclose known cardiac side effects, and its misappropriation of inventor John's intellectual property. The paper also identifies parties responsible for regulating compounding pharmacies, evaluates PharmaCARE's potential legal exposure, discusses how the company used U.S. patent law for its own benefit, identifies potential litigants, and assesses John's standing as a protected whistleblower.
- Ethical Issues Surrounding PharmaCARE and CompCARE: FDA evasion, marketing violations, and IP ethics
- Regulation of Compounding Pharmacies and Legal Exposure: Who regulates compounding pharmacies and PharmaCARE's liability
- Using U.S. Intellectual Property Law: How PharmaCARE exploited patent law for AD23
- Compensation and Recognition of John's Contributions: Fair compensation options PharmaCARE should have provided John
- Potential Litigants Against PharmaCARE: Who can sue PharmaCARE and on what grounds
- John's Claim as a Whistleblower: John's whistleblower status and legal protections
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper systematically addresses distinct legal and ethical dimensions — FDA evasion, intellectual property misuse, marketing violations, and whistleblower protections — in clearly separated sections, making the argument easy to follow.
- It grounds claims in cited statutory and regulatory sources, including the 2013 FDA compounding legislation and the Whistleblower Protection Enhancement Act, lending credibility to its legal analysis.
- The paper effectively uses the internal memo as a recurring evidentiary anchor, connecting multiple ethical and legal arguments to a concrete piece of evidence.
Key academic technique demonstrated
The paper demonstrates applied legal-ethical analysis: it identifies a real-world corporate scenario, maps the conduct onto relevant legal frameworks (patent law, FDA regulation, whistleblower statutes), and evaluates liability and moral responsibility. This technique — moving from fact pattern to legal standard to normative judgment — is characteristic of business law case analysis.
Structure breakdown
The paper opens with ethical violations (FDA evasion, marketing misconduct, IP ethics), then shifts to regulatory accountability and legal exposure, followed by a section on how PharmaCARE weaponized IP law for its own benefit. Two subsequent sections address potential plaintiffs and the appropriate compensation owed to John. The paper closes with an assessment of John's whistleblower status and the protections he should receive. Each section builds on the established fact pattern without repeating it unnecessarily.
Ethical Issues Surrounding PharmaCARE and CompCARE
PharmaCARE intentionally bypassed the Food and Drug Administration when it established CompCARE as a compounding pharmacy. This was done in order to avoid FDA scrutiny, which indicates that the company was aware of the side effects the drug would have on patients. By evading FDA review and approval, PharmaCARE was able to sell the new formulation on a prescription basis without seeking the required approvals. CompCARE was not supposed to market directly to consumers, but it nonetheless conducted direct marketing to consumers and hospitals. Furthermore, the company encouraged doctors to fax lists of fictitious patient names in order to create the appearance that physicians — rather than the company — were prescribing the drug to patients.
When reports began surfacing indicating that the drug was causing heart attacks, the company did not remove it from the market. The company ignored the data and continued to market the drug without informing patients of its side effects (Halbert & Ingulli, 2011). This was ethically wrong because the company is ethically obligated to disclose a drug's side effects, allowing patients to make an informed decision about whether to continue taking it. The company was in direct violation of direct-to-consumer marketing and advertising regulations.
PharmaCARE also violated intellectual property ethics. The company used the invention that John and his team had developed for its own gain. The prerequisites for obtaining a patent hindered John and his team from securing one for AD23. The company did not respect John's inventive contributions and replicated his work for its own profit. PharmaCARE opted to pay John large bonuses from drug sales — an arrangement that still violated intellectual property ethics. PharmaCARE subsequently sold CompCARE to a store chain shortly before AD23 was linked to cardiac deaths. That sale transferred the intellectual property from PharmaCARE to WellCo, meaning John's invention had been sold without his consent or approval. Although John was employed by PharmaCARE when he developed the drug, the company should have recognized his ownership interest in the intellectual property and not disposed of it in the manner it did.
Regulation of Compounding Pharmacies and Legal Exposure
State pharmacy boards are responsible for regulating compounding pharmacies. No drugs produced by a compounding pharmacy are subjected to FDA premarket examination, and no other regulatory body examines such drugs before they reach the market. This is because compounding pharmacies do not manufacture drugs in the traditional sense; rather, they modify a drug's ingredients to create a new medication tailored to a specific patient need or treatment. The quality and safety of consumer products is, broadly speaking, the responsibility of the FDA (Liu, Knox, & Brushwood, 2013). Therefore, the FDA should have investigated the drug when reports of adverse patient effects first emerged. The legislation signed by President Obama in November 2013 grants the FDA authority to oversee compounding pharmacies (U.S. Food and Drug Administration, 2013). This legislation gives the FDA sufficient power over compounding pharmacies, but its enforcement has not been fully effective.
PharmaCARE intentionally avoided FDA scrutiny by forming a compounding pharmacy, which allowed the company to manufacture and sell the drug much faster. The FDA should have examined the drug to determine whether it contained any dangerous compounds, which would have helped reduce the number of cardiac deaths associated with its use.
It is unlikely that PharmaCARE will face legal exposure solely for forming a compounding pharmacy, but it could face significant legal liability for failing to inform consumers of the drug's side effects. The company ignored reports that the drug was causing heart attacks and chose to continue selling it. If evidence substantiates this fact, the relatives of deceased patients could bring suit against the company. The internal memo in John's possession is sufficient to expose the company to legal action. Marketing a drug while concealing its known dangers is illegal and has the clear potential to create substantial liability for PharmaCARE.
References
Halbert, T., & Ingulli, E. (2011). Law and ethics in the business environment. Boston, MA: Cengage Learning.
Kim, Y. K., Lee, K., Park, W. G., & Choo, K. (2012). Appropriate intellectual property protection and economic growth in countries at different levels of development. Research Policy, 41(2), 358–375.
Liu, W., Knox, C. A., & Brushwood, D. B. (2013). Discretion of the Food and Drug Administration to enforce compounding rules. American Journal of Health-System Pharmacy, 70(17), 1538–1543.
Peffer, S. L., Bocheko, A., Del Valle, R. E., Osmani, A., Peyton, S., & Roman, E. (2013). Whistle where you work? The ineffectiveness of the Federal Whistleblower Protection Act of 1989 and the promise of the Whistleblower Protection Enhancement Act of 2012. Review of Public Personnel Administration.
U.S. Food and Drug Administration. (2013). The impact of direct-to-consumer advertising. Retrieved from
Always verify citation format against your institution’s current style guide requirements.